AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...

CEO warns continent’s advantage in the industry could fade as companies build new high-tech factories elsewhere ...

NHS patients risk losing access to the world’s best medicines unless the UK spends more on developing new treatments, the ...

South Korea's drug safety ministry said on Wednesday it granted final approval for a shipment of 1.57 million doses of ...

AstraZeneca is the biggest drugmaker in Britain and its £193 billion ($253 billion) market capitalization tops the London Stock Exchange.

AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a ...

Drugmakers feel empowered to resist foreign price controls — confident that the Trump administration will have their backs.

Under the model, set to start next year, the CMS will negotiate lower prices for Medicaid programs linked to those paid in ...

AstraZeneca said work on its new plant north of Charlottesville will begin immediately and be open within five years.

The “most favored nation” (MFN) drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the ...

Novo Nordisk and Eli Lilly said they've agreed to sell their blockbuster drugs Wegovy and Zepbound at a discount.

ASTRAZENECA delivered better-than-expected third quarter earnings and retained its full-year forecasts on Thursday, with strong sales of its blockbuster cancer and cardiovascular drugs.